SLC2A1 and cancer: Surprisingly, the co-administration of a GLUT1 inhibitor (EDG) paradoxically increased the potency of Au13c (GI50 dropped to 3.3 μM), suggesting that cancer cells may compensate via upregulation of alternative glucose transporters, such as GLUT3, which might transport this compound more effectively.